Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis

0498128 - ÚI 2019 RIV GB eng J - Článek v odborném periodiku
Krištofíková, Z. - Říčný, J. - Kaping, D. - Klaschka, Jan - Kotoučová, J. - Bartoš, A.
Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis.
Biomarkers in Medicine. Roč. 12, č. 12 (2018), s. 1331-1340. ISSN 1752-0363. E-ISSN 1752-0371
Grant CEP: GA ČR(CZ) GBP304/12/G069
Grant ostatní: GA MŠk(CZ) LO1611
Institucionální podpora: RVO:67985807
Klíčová slova: 17β-hydroxysteroid dehydrogenase type 10 * Alzheimer’s disease * CSF biomarkers * cyclophilin D * diagnosis * mitochondrial dysfunction * multiple sclerosis * neuroinflammation * parkin * protein interactions
Obor OECD: Neurosciences (including psychophysiology
Impakt faktor: 2.268, rok: 2018

Aim:We aimed to characterize the role of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. Materials & methods: We estimated levels of 17β-HSD10, amyloid β 1–42, cyclophilin D, 17β-HSD10-cyclophilin D complexes or 17β-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. Results: The increase in 17β-HSD10 levels or in 17β-HSD10-parkin complexes and links to leukocytes were found only in relapsing–remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60–63% compared with controls. Conclusion: Increased CSF levels of 17β-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17β-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.
Trvalý link: http://hdl.handle.net/11104/0290541